tiprankstipranks
Advertisement
Advertisement
3 High-Risk, High-Reward Stocks to Buy Now, According to Analysts
PremiumMarket News3 High-Risk, High-Reward Stocks to Buy Now, According to Analysts
1M ago
Nuvation Bio Shareholders Approve Directors and Executive Compensation
Premium
Company Announcements
Nuvation Bio Shareholders Approve Directors and Executive Compensation
1M ago
Nuvation Bio’s Ibtrozi shows improved quality of life in NSCLC trial
Premium
The Fly
Nuvation Bio’s Ibtrozi shows improved quality of life in NSCLC trial
1M ago
Yaron Werber Reiterates Buy on Ibtrozi Maker, Citing Growing First‑Line Adoption and Market Share Gains in ROS1‑Positive Lung Cancer Despite Near‑Term Estimate Cuts
PremiumRatingsYaron Werber Reiterates Buy on Ibtrozi Maker, Citing Growing First‑Line Adoption and Market Share Gains in ROS1‑Positive Lung Cancer Despite Near‑Term Estimate Cuts
2M ago
Nuvation Bio reports Q1 EPS 1c, consensus 5c
Premium
The Fly
Nuvation Bio reports Q1 EPS 1c, consensus 5c
2M ago
Analyst Maintains Buy Rating on Taletrectinib Developer, Reaffirming $17 12-Month Price Target on Strengthening ROS1+ NSCLC Outlook
Premium
Ratings
Analyst Maintains Buy Rating on Taletrectinib Developer, Reaffirming $17 12-Month Price Target on Strengthening ROS1+ NSCLC Outlook
2M ago
Nuvation Bio falls -25.3%
PremiumThe FlyNuvation Bio falls -25.3%
4M ago
Nuvation Bio falls -25.3%
Premium
The Fly
Nuvation Bio falls -25.3%
4M ago
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks
Premium
Company Announcements
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100